Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

University of Michigan

Status and phase: Completed; Phase 2

Conditions: Idiopathic Pulmonary Fibrosis

Treatments: Drug: azathioprine/prednisone; Drug: zileuton

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00262405

P50HL056402-06 (U.S. NIH Grant/Contract)

1995-0304

Details and patient eligibility

About

Open label trial of zileuton compared to azathioprine/prednisone for patients with idiopathic pulmonary fibrosis. Study subjects will undergo a detailed clinical, radiographic, and physiologic assessment at baseline. Subjects will be monitored off treatment for three months for changes in symptoms and physiology. Subjects will then be randomized to six months of treatment with zileuton or azathioprine/prednisone. The primary endpoint of this trial is change in LTB4 levels in bronchoalveolar lavage fluid following six months of treatment. Secondary endpoints are progression free survival, change in dyspnea, change in quality of life, and change in physiology.

Enrollment: 44 patients

Sex: All

Ages: 35 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of idiopathic pulmonary fibrosis
• Taking < 15 mg prednisone for at least 30 days prior to screening
• Age 35-80, inclusive
• Able to understand a written informed consent and comply with the study protocol

Exclusion criteria

• Significant environmental exposure
• Diagnosis of collagen vascular disease
• Evidence of active infection
• Clinically significant cardiac disease Myocardial infarction, coronary artery bypass or angioplasty within 6mo Unstable angina pectoris Congestive heart failure requiring hospitalization within 6 months Uncontrolled arrhythmia
• Poorly controlled or severe diabetes mellitus
• Pregnancy or lactation
• Women of childbearing potential not using a medically approved means of contraception (i.e. oral contraceptives, intrauterine devices, diaphragm, Norplant)
• Current enrollment in another experimental protocol

Physiologic Criteria:

• FEV1/FVC < 0.60

Laboratory Criteria:

• Total bilirubin > 1.5 X upper limit normal
• AST or ALT > 3X upper limit normal
• Alkaline phosphatase > 3X upper limit normal
• White blood cell count < 2,500/mm3
• Hematocrit < 30%
• Platelets < 100,000/mm3
• Prothrombin time INR > 1.5

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

44 participants in 2 patient groups

zileuton

Experimental group

Description:

Zileuton

Treatment:

Drug: zileuton

azathioprine/prednisone

Active Comparator group

Description:

azathioprine/prednisone

Treatment:

Drug: azathioprine/prednisone